Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
house dust mite allergoid
- Development stage
- Phase 3
- Lead developer
- Allergopharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
House dust mite allergoid is a subcutaneous allergen immunotherapy (SCIT) developed by Allergopharma for the treatment of house dust mite-induced allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma. It consists of chemically modified allergen extracts (allergoids) from the house dust mites *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, which are cross-linked with formaldehyde and glutaraldehyde and adsorbed onto aluminum hydroxide as a depot adjuvant. This chemical modification reduces the IgE-binding capacity of the allergens, thereby minimizing the risk of IgE-mediated systemic allergic reactions (anaphylaxis) while preserving the T-cell epitopes necessary to induce immunological tolerance. The therapy works by promoting a shift from a Th2-dominated allergic response to a Th1/Treg-mediated tolerant state, inducing the production of allergen-specific IgG4 blocking antibodies and regulatory T cells.
- Brand names
- AcaroidAllergovit MilbenAllergovit Mites
- Other names
- house dust mite allergoid immunotherapysubcutaneous house dust mite allergoid immunotherapy
02
Targets
FCER1 (Fc epsilon RI receptor)IL10 (Interleukin-10)MHC II (Major histocompatibility complex class II receptor)TGFB (GARP–latent transforming growth factor beta 1 complex)BCR (Immunoglobulin G B Cell Receptor)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)IgE (Immunoglobulin E)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on house dust mite allergoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on house dust mite allergoid.